(0.22%) 5 142.75 points
(0.21%) 38 522 points
(0.32%) 17 903 points
(-0.99%) $83.02
(1.66%) $1.955
(-0.33%) $2 339.50
(-0.24%) $27.47
(0.30%) $924.90
(-0.16%) $0.933
(-0.10%) $11.01
(-0.24%) $0.798
(0.76%) $92.57
@ $92.30
Išleistas: 14 vas. 2024 @ 16:40
Grąža: 11.80%
Ankstesnis signalas: vas. 13 - 16:30
Ankstesnis signalas:
Grąža: 0.53 %
Live Chart Being Loaded With Signals
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 18 627.00 |
Vidutinė apimtis | 43 153.00 |
Rinkos kapitalizacija | 556.61M |
EPS | $0 ( 2024-02-05 ) |
Kita pelno data | ( $2.33 ) 2024-05-24 |
Last Dividend | $0.160 ( 2023-11-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | 607.00 |
ATR14 | $0.499 (0.48%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Sullivan John James | Sell | 450 | Non Qualified Stock Option |
2024-04-02 | Sakys John | Sell | 2 500 | Non Qualified Stock Option |
2024-04-02 | Owens Gary M | Sell | 5 000 | Non Qualified Stock Options |
2024-04-02 | Archbold Brian David | Sell | 420 | Non Qualified Stock Option |
2024-01-08 | Archbold Brian David | Sell | 290 | Non Qualified Stock Option |
INSIDER POWER |
---|
12.65 |
Last 100 transactions |
Buy: 73 301 | Sell: 52 584 |
Mesa Laboratories Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Mesa Laboratories Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $219.08M |
Bruto pelnas: | $133.69M (61.02 %) |
EPS: | $0.170 |
FY | 2023 |
Pajamos: | $219.08M |
Bruto pelnas: | $133.69M (61.02 %) |
EPS: | $0.170 |
FY | 2022 |
Pajamos: | $184.34M |
Bruto pelnas: | $109.09M (59.18 %) |
EPS: | $0.360 |
FY | 2021 |
Pajamos: | $133.94M |
Bruto pelnas: | $87.01M (64.97 %) |
EPS: | $0.660 |
Financial Reports:
No articles found.
Mesa Laboratories Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.200 | 2003-11-26 |
Last Dividend | $0.160 | 2023-11-29 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-15 | |
Next Payout Date | N/A | |
# dividends | 81 | -- |
Total Paid Out | $11.06 | -- |
Avg. Dividend % Per Year | 0.19% | -- |
Score | 4.41 | -- |
Div. Sustainability Score | 7.61 | |
Div.Growth Potential Score | 5.87 | |
Div. Directional Score | 6.74 | -- |
Year | Amount | Yield |
---|---|---|
2003 | $0.200 | 3.07% |
2004 | $0.410 | 4.07% |
2005 | $0.500 | 3.85% |
2006 | $0.390 | 2.60% |
2007 | $0.340 | 1.80% |
2008 | $0.400 | 1.54% |
2009 | $0.410 | 2.27% |
2010 | $0.450 | 1.70% |
2011 | $0.490 | 1.63% |
2012 | $0.530 | 1.29% |
2013 | $0.570 | 1.08% |
2014 | $0.610 | 0.79% |
2015 | $0.640 | 0.80% |
2016 | $0.640 | 0.64% |
2017 | $0.640 | 0.52% |
2018 | $0.640 | 0.51% |
2019 | $0.640 | 0.31% |
2020 | $0.640 | 0.26% |
2021 | $0.640 | 0.23% |
2022 | $0.640 | 0.20% |
2023 | $0.640 | 0.37% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00445 | 1.500 | 9.91 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00128 | 1.200 | 9.96 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00241 | 1.500 | -1.084 | -1.626 | [0.1 - 1] |
payoutRatioTTM | 3.63 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 2.68 | 0.800 | 1.606 | 1.285 | [1 - 3] |
quickRatioTTM | 1.503 | 0.800 | 5.87 | 4.69 | [0.8 - 2.5] |
cashRatioTTM | 0.639 | 1.500 | 7.56 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.318 | -1.500 | 4.70 | -7.04 | [0 - 0.6] |
interestCoverageTTM | -2.03 | 1.000 | -1.862 | -1.862 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.12 | 2.00 | 7.29 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 7.55 | 2.00 | 6.23 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.586 | -1.500 | 7.66 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.610 | 1.000 | 3.16 | 3.16 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0438 | 1.000 | -2.88 | -2.88 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.185 | 1.000 | -0.0812 | -0.0812 | [0.2 - 2] |
assetTurnoverTTM | 0.287 | 0.800 | -1.420 | -1.136 | [0.5 - 2] |
Total Score | 7.61 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 587.03 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00241 | 2.50 | -0.697 | -1.626 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 7.55 | 2.00 | 7.48 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.620 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.12 | 2.00 | 7.29 | 10.00 | [0 - 30] |
payoutRatioTTM | 3.63 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 1.693 | 1.500 | 2.05 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.206 | 1.000 | 7.36 | 0 | [0.1 - 0.5] |
Total Score | 5.87 |
Mesa Laboratories Inc
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.